Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAGI3 | Q5TCQ9 | 1/20 | 0.56 |
| ▸ | TASP1 | Q9H6P5 | 1/20 | 0.52 |
| ▸ | CASP1 | P29466 | 1/20 | 0.47 |
| ▸ | CASP3 | P42574 | 1/20 | 0.47 |
| ▸ | CASP4 | P49662 | 1/20 | 0.47 |
| ▸ | CASP5 | P51878 | 1/20 | 0.47 |
| ▸ | CASP9 | P55211 | 1/20 | 0.47 |
| ▸ | CASP6 | P55212 | 1/20 | 0.47 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.47 |
| ▸ | CASP10 | Q92851 | 1/20 | 0.47 |
| ▸ | ENPEP | Q07075 | 5/20 | 0.44 |
| ▸ | CTSD | P07339 | 3/20 | 0.42 |
| ▸ | REN | P00797 | 1/20 | 0.41 |
| ▸ | BACE1 | P56817 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29974620 | 1.00 | MAGI3 (0.56) | MAGI3TASP1CASP1CASP3CASP4 | |
| SCHEMBL29974699 | 0.96 | MAGI3 (0.53) | MAGI3TASP1CASP1CASP3CASP4 | |
| SCHEMBL7067113 | 0.86 | TASP1 (0.62) | MAGI3TASP1CASP1CASP3CASP4 | |
| SCHEMBL29975231 | 0.84 | ACE (0.53) | MAGI3TASP1CASP1CASP3CASP4 | |
| SCHEMBL7610443 | 0.83 | CTSS (0.48) | MAGI3CASP1CASP3CASP4CASP5 | |
| SCHEMBL7610438 | 0.83 | CTSS (0.48) | MAGI3CASP1CASP3CASP4CASP5 | |
| SCHEMBL30682563 | 0.83 | GNPAT (0.43) | MAGI3TASP1BACE1 | |
| SCHEMBL20335576 | 0.83 | TASP1 (0.47) | MAGI3TASP1CASP1CASP3CASP4 | |
| SCHEMBL21515972 | 0.83 | TASP1 (0.47) | MAGI3TASP1CASP1CASP3CASP4 | |
| SCHEMBL20335572 | 0.83 | TASP1 (0.47) | MAGI3TASP1CASP1CASP3CASP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230399361-A1 | MACROCYCLIC PEPTIDES | UNIVERSITY OF NOTRE DAME DU LAC | 2023-12-14 | — | — | US | claimed |
| US-20240116984-A1 | MODIFIED PEPTIDES FOR THE INHIBITION OF ABNORMAL TAU ACCUMULATION | NATIONAL SCIENCE FOUNDATION | 2024-04-11 | — | — | US | disclosed |
| EP-4329791-A1 | MODIFIED PEPTIDES FOR THE INHIBITION OF ABNORMAL TAU ACCUMULATION | University of Notre Dame du Lac (US) | 2024-03-06 | — | — | EP | disclosed |
| US-20230399361-A1 | MACROCYCLIC PEPTIDES | UNIVERSITY OF NOTRE DAME DU LAC | 2023-12-14 | — | — | US | disclosed |
| WO-2022232007-A1 | MODIFIED PEPTIDES FOR THE INHIBITION OF ABNORMAL TAU ACCUMULATION | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2022-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240116984-A1 | MODIFIED PEPTIDES FOR THE INHIBITION OF ABNORMAL TAU ACCUMULATION | PRNP, MAPT, APP | MAGI3 1172/4885TASP1 590/4885CASP1 2252/4885 |
| US-20230399361-A1 | MACROCYCLIC PEPTIDES | APP, MAPT, NEFM | MAGI3 2744/4885TASP1 603/4885CASP1 880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.